Analysts Set Liquidia Co. (NASDAQ:LQDA) Target Price at $21.00

Liquidia Co. (NASDAQ:LQDA) has earned a consensus rating of “Moderate Buy” from the six research firms that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $21.00.

Several research firms recently commented on LQDA. HC Wainwright reissued a “buy” rating and set a $32.00 target price on shares of Liquidia in a research note on Wednesday, May 15th. Oppenheimer assumed coverage on Liquidia in a report on Tuesday, June 25th. They issued a “market perform” rating on the stock. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 target price on shares of Liquidia in a report on Monday, June 3rd.

Insider Buying and Selling at Liquidia

In other news, General Counsel Russell Schundler sold 2,060 shares of the firm’s stock in a transaction on Friday, April 12th. The stock was sold at an average price of $14.58, for a total value of $30,034.80. Following the completion of the sale, the general counsel now owns 486,027 shares of the company’s stock, valued at $7,086,273.66. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other Liquidia news, CEO Roger Jeffs sold 8,360 shares of the company’s stock in a transaction that occurred on Friday, April 12th. The shares were sold at an average price of $14.58, for a total value of $121,888.80. Following the transaction, the chief executive officer now owns 826,985 shares in the company, valued at approximately $12,057,441.30. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, General Counsel Russell Schundler sold 2,060 shares of the stock in a transaction that occurred on Friday, April 12th. The stock was sold at an average price of $14.58, for a total transaction of $30,034.80. Following the completion of the sale, the general counsel now owns 486,027 shares of the company’s stock, valued at approximately $7,086,273.66. The disclosure for this sale can be found here. Insiders have sold a total of 18,653 shares of company stock valued at $270,409 in the last three months. 31.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Liquidia

A number of hedge funds have recently modified their holdings of LQDA. Boston Partners purchased a new position in Liquidia in the first quarter valued at about $762,000. Farallon Capital Management LLC acquired a new position in Liquidia in the first quarter worth approximately $30,311,000. Whitefort Capital Management LP raised its position in Liquidia by 45.8% during the first quarter. Whitefort Capital Management LP now owns 337,607 shares of the company’s stock valued at $4,980,000 after acquiring an additional 106,049 shares in the last quarter. California State Teachers Retirement System lifted its stake in Liquidia by 491.2% in the first quarter. California State Teachers Retirement System now owns 46,181 shares of the company’s stock valued at $681,000 after acquiring an additional 38,369 shares during the last quarter. Finally, Janus Henderson Group PLC bought a new stake in Liquidia in the first quarter worth approximately $502,000. 64.54% of the stock is owned by institutional investors and hedge funds.

Liquidia Price Performance

Shares of NASDAQ:LQDA opened at $12.04 on Tuesday. The stock has a market cap of $919.21 million, a price-to-earnings ratio of -7.72 and a beta of 0.25. Liquidia has a 12 month low of $5.71 and a 12 month high of $16.99. The stock’s 50 day moving average price is $12.82 and its 200 day moving average price is $13.32.

Liquidia (NASDAQ:LQDA) last announced its earnings results on Monday, May 13th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.22). Liquidia had a negative net margin of 674.42% and a negative return on equity of 177.83%. The firm had revenue of $2.97 million for the quarter, compared to the consensus estimate of $4.31 million. On average, sell-side analysts expect that Liquidia will post -1.32 EPS for the current year.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).